12 Health Care Stocks Moving In Wednesday's Intraday Session

Benzinga · 03/11 17:06
Gainers
- Acurx Pharmaceuticals (NASDAQ:ACXP) shares rose 89.0% to $5.48 during Wednesday's regular session. The market value of their outstanding shares is at $7.3 million.
- 60 Degrees (NASDAQ:SXTP) stock increased by 47.6% to $2.77. The market value of their outstanding shares is at $2.4 million.
- Ocugen (NASDAQ:OCGN) stock moved upwards by 30.79% to $2.31. The market value of their outstanding shares is at $579.3 million.
- Adagene (NASDAQ:ADAG) stock increased by 26.79% to $3.71. The company's market cap stands at $138.0 million.
- Scienture Holdings (NASDAQ:SCNX) stock increased by 26.24% to $0.49. The company's market cap stands at $15.7 million.
- SCWorx (NASDAQ:WORX) stock rose 25.59% to $0.16. The market value of their outstanding shares is at $2.0 million.
Losers
- Co-Diagnostics Inc Registered Shs (NASDAQ:CODX) stock fell 30.9% to $3.04 during Wednesday's regular session. The market value of their outstanding shares is at $9.2 million.
- Quantum BioPharma (NASDAQ:QNTM) shares declined by 23.56% to $2.14. The market value of their outstanding shares is at $10.7 million.
- Aptevo Therapeutics (NASDAQ:APVO) shares decreased by 20.0% to $4.16. The company's market cap stands at $8.1 million.
- MiNK Therapeutics (NASDAQ:INKT) stock decreased by 15.62% to $11.4. The company's market cap stands at $63.4 million.
- AN2 Therapeutics (NASDAQ:ANTX) shares decreased by 14.11% to $4.69. The company's market cap stands at $149.6 million.
- Skye Bioscience (NASDAQ:SKYE) shares declined by 14.01% to $0.69. The company's market cap stands at $25.6 million. The company's, Q4 earnings came out yesterday. See Also: www.benzinga.com/money/best-healthcare-stocks/
This article was generated by Benzinga's automated content engine and reviewed by an editor.
Disclaimer:This article represents the opinion of the author only. It does not represent the opinion of Webull, nor should it be viewed as an indication that Webull either agrees with or confirms the truthfulness or accuracy of the information. It should not be considered as investment advice from Webull or anyone else, nor should it be used as the basis of any investment decision.